Canopy Growth (CGC) Shares Outstanding (Diluted Average) (2019 - 2025)
Canopy Growth's (CGC) quarterly Shares Outstanding (Diluted Average) came in at $193.3 million in Q4 2025, up 144.82% year-on-year from $79.0 million in Q4 2024, and up 14.97% quarter-over-quarter from $168.1 million in Q3 2025.
Canopy Growth (CGC) Shares Outstanding (Diluted Average) (2019 - 2025) Analysis & Trends
Canopy Growth has disclosed Shares Outstanding (Diluted Average) across 7 years of filings, most recently posting $193.3 million for Q4 2025.
- Shares Outstanding (Diluted Average) for Q4 2025 came in at $193.3 million, up 144.82% year-over-year; the trailing twelve-month figure through Dec 2025 was $193.3 million (up 144.82% YoY), and the FY2025 annual result was $75.0 million, up 35.05% from the prior year.
- Shares Outstanding (Diluted Average) came in at $193.3 million for Q4 2025 at Canopy Growth, up from $168.1 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $361.6 million in Q3 2022 to a low of $30.9 million in Q1 2022.
- The 5-year median for Shares Outstanding (Diluted Average) is $77.0 million (2024), against an average of $150.8 million.
- Across the five-year window, Shares Outstanding (Diluted Average) plunged 89.48% in 2022 and soared 176.18% in 2025, its largest moves.
- Canopy Growth's Shares Outstanding (Diluted Average) stood at $312.4 million in 2021, then plunged by 88.54% to $35.8 million in 2022, then surged by 70.07% to $60.9 million in 2023, then gained by 29.64% to $79.0 million in 2024, then jumped by 144.82% to $193.3 million in 2025.
- The last three Shares Outstanding (Diluted Average) figures came in at $193.3 million (Q4 2025), $168.1 million (Q3 2025), and $135.9 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.97 Bn | 36.23 Bn | 1.97 Bn | 1.18 Bn |
| 2 | Zoetis | 33.59 Bn | 31.65 Bn | 1.62 Bn | 422.40 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 47.20 Mn |
| 4 | Neurocrine Biosciences | 16.10 Bn | 14.78 Bn | 800.70 Mn | 103.40 Mn |
| 5 | Aurora Cannabis | 15.56 Bn | 15.47 Bn | 21.72 Mn | - |
| 6 | Elanco Animal Health | 12.04 Bn | 11.61 Bn | 785.00 Mn | 506.00 Mn |
| 7 | Alkermes | 7.36 Bn | 6.84 Bn | -116.06 Mn | - |
| 8 | Lantheus Holdings | 6.74 Bn | 6.24 Bn | 230.92 Mn | - |
| 9 | Liquidia | 6.27 Bn | 6.04 Bn | 121.79 Mn | 101.11 Mn |
| 10 | Canopy Growth | 11.16 Mn | -137.54 Mn | 15.39 Mn | 193.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 193.32 Mn |
| Sep 30, 2025 | 168.15 Mn |
| Jun 30, 2025 | 135.91 Mn |
| Mar 31, 2025 | 74.96 Mn |
| Dec 31, 2024 | 78.96 Mn |
| Sep 30, 2024 | 60.88 Mn |
| Jun 30, 2024 | 57.94 Mn |
| Mar 31, 2024 | 55.50 Mn |
| Dec 31, 2023 | 60.91 Mn |
| Sep 30, 2023 | 53.43 Mn |
| Jun 30, 2023 | 40.98 Mn |
| Mar 31, 2023 | 34.30 Mn |
| Dec 31, 2022 | 35.81 Mn |
| Sep 30, 2022 | 361.59 Mn |
| Jun 30, 2022 | 312.53 Mn |
| Mar 31, 2022 | 30.89 Mn |
| Dec 31, 2021 | 312.43 Mn |
| Sep 30, 2021 | 325.04 Mn |
| Jun 30, 2021 | 329.11 Mn |
| Mar 31, 2021 | 293.65 Mn |